Cargando…

1695. Tebipenem: An Oral Carbapenem with activity against Multi-drug Resistant Urinary Tract Infection isolates of Escherichia coli collected from US Medical Centers during 2019

BACKGROUND: Escherichi coli (EC) is a predominant urinary tract infection (UTI) pathogen where increasing prevalence of extended spectrum-β-lactamase (ESBL) continues to compromise the use of currently available oral antibiotics. ESBL-producing EC exhibit coresistance to the fluoroquinolones (FQs) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Critchley, Ian A, Cotroneo, Nicole S, Pucci, Michael J, Jain, Akash, Mendes, Rodrigo E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778108/ http://dx.doi.org/10.1093/ofid/ofaa439.1873

Ejemplares similares

1057. Tebipenem In vitro Activity Against a Collection of Pathogens Responsible for Urinary Tract Infections in the US
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017
por: Critchley, Ian A., et al.
Publicado: (2019)

1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates
por: Arends, S J Ryan, et al.
Publicado: (2021)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

1254. Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and in vitro Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1041. In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
por: Arends, S J Ryan, et al.
Publicado: (2021)

1044. In vitro Activity of Tebipenem Against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant
por: Arends, S J Ryan, et al.
Publicado: (2021)

1465. Resistance to Oral Antibiotics Among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017
por: Critchley, Ian A, et al.
Publicado: (2019)

150. Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
por: VanScoy, Brian D, et al.
Publicado: (2022)

Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections
por: Ranasinghe, Ama, et al.
Publicado: (2022)

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

1281. An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations
por: VanScoy, Brian D, et al.
Publicado: (2021)

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
por: VanScoy, B. D., et al.
Publicado: (2023)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects
por: Gupta, Vipul K., et al.
Publicado: (2022)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

Crystal structure of tebipenem pivoxil
por: Tang, Chao, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
por: Ganesan, H., et al.
Publicado: (2023)

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment
por: Patel, Gina, et al.
Publicado: (2022)

2159. Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022
por: Arends, S J Ryan, et al.
Publicado: (2023)

Phenotypic and Molecular Characterization of Carbapenems Resistant Escherichia coli Isolated from Patients with Urinary Tract Infections in Ardabil Province, Iran
por: khavandi, Shabnam, et al.
Publicado: (2022)

Tebipenem, a New Carbapenem Antibiotic, Is a Slow Substrate That Inhibits the β-Lactamase from Mycobacterium tuberculosis
por: Hazra, Saugata, et al.
Publicado: (2014)

Urinary Tract Infection Caused by Capnophilic Escherichia coli
por: Tena, Daniel, et al.
Publicado: (2008)

An Approach to Uropathogenic Escherichia Coli in Urinary Tract Infections
por: Ranjan, K Prabhat, et al.
Publicado: (2010)

1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020
por: Arends, S J Ryan, et al.
Publicado: (2021)

LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020)

Isolation and Characterization of Carbapenem-Resistant Escherichia coli Carrying bla(NDM) and mcr-1 from Recurrent Urinary Tract Infection Patient
por: Chen, Liang, et al.
Publicado: (2023)

The golden age of Brazil, 1695-1750; growing pains of a colonial society
por: Boxer, Charles Ralph, 1904-
Publicado: (1962)

Clinical and laboratory standards institute versus European committee for antimicrobial susceptibility testing guidelines for interpretation of carbapenem antimicrobial susceptibility results for Escherichia coli in urinary tract infection (UTI)
por: Sahu, Chinmoy, et al.
Publicado: (2018)

Food Reservoir for Escherichia coli Causing Urinary Tract Infections
por: Vincent, Caroline, et al.
Publicado: (2010)

Food Reservoir for Escherichia coli Causing Urinary Tract Infections
por: Giufrè, Maria, et al.
Publicado: (2010)

How to Make It in the Urinary Tract: A Tutorial by Escherichia coli
por: Jorgensen, Ine, et al.
Publicado: (2012)

Resistance patterns of Escherichia coli causing urinary tract infection
por: Ferdosi-Shahandashti, Elaheh, et al.
Publicado: (2015)

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

1153. ESBL Producing E. coli Urinary Tract Infections in Children: Is Carbapenem Always Necessary?
por: del Carmen, Ruiz Cabrales Diva, et al.
Publicado: (2021)

Johann Jakob Wepfer (1620–1695) als klinischer Praktiker
por: Librach, I. M.
Publicado: (1971)

1695 Implementation of Tuberculosis Infection Control Guidelines in South India
por: Hemalatha, Jothimani, et al.
Publicado: (2014)

An Unusual Carbapenem Resistant Escherichia coli Carrying Plasmid-mediated AmpC and Mutated ompC in A Patient with Recurrent Urinary Tract Infections
por: Larkin, Paige M.K., et al.
Publicado: (2020)

Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model
por: Neville, Lewis F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c55ob3fsnbjfpg9hm2fpfgpfco